Home > Insider Trading > Filing (0001209191-14-058497)

Filing Details

Accession Number:: 0001209191-14-058497
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-09-17 20:58:48
Reporting Period:: 2014-09-16

Filing Date:: 2014-09-17
Accepted Time:: 2014-09-17 20:58:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463729	Receptos Inc.	RCPT	Pharmaceutical Preparations (2834)	264190792

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1396943	K Graham Cooper	10835 Road To The Cure, Suite 205 San Diego CA 92121	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-09-16	50,000	$5.10	50,000	No	4	M	Direct
Common Stock	Disposition	2014-09-16	50,000	$61.30	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2014-09-16	50,000	$0.00	50,000	$5.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
96,666		2023-02-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.38 to $62.31 per share, inclusive. The reporting person undertakes to provide to Receptos, Inc., any security holder of Receptos, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option, representing a right to purchase a total of 146,666 shares, became exercisable as follows: (i) 106,666 shares vested 25% on the one-year anniversary of February 15, 2013 and 1/48th of the shares vest each month thereafter for the remaining three years; and (ii) commencement of vesting on the remaining 40,000 shares was subject to the fulfillment of a milestone event consisting of the dosing of the first patient in Receptos' first clinical trial for a product candidate where the FDA (or foreign equivalent) would recognize such a clinical trial, assuming successful completion, as a pivotal study for a product candidate for submission of a new Drug Application or a Biologics License Application, and any Phase 3 clinical study will be presumed to satisfy this requirement. (Continued in footnote 4)
The shares vested 25% immediately upon the achievement of the milestone and 1/48th of the shares vest each month thereafter for three years, not to exceed February 15, 2018, at which time any of such shares remaining unvested will vest. The option is subject to vesting acceleration in the event of certain corporate or change of control transactions.